Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC7 | Q8WUI4 | 6/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.52 |
| ▸ | MMP2 | P08253 | 2/20 | 0.51 |
| ▸ | MMP9 | P14780 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6954199 | 1.00 | HDAC7 (0.52) | HDAC7HDAC1MMP2MMP9SMN1; SMN2 | |
| SCHEMBL7898753 | 1.00 | HDAC7 (0.52) | HDAC7HDAC1MMP2MMP9SMN1; SMN2 | |
| SCHEMBL6510657 | 0.95 | HDAC1 (0.58) | HDAC7HDAC1MMP2MMP9SMN1; SMN2 | |
| SCHEMBL6966437 | 0.95 | HDAC1 (0.58) | HDAC7HDAC1MMP2MMP9SMN1; SMN2 | |
| SCHEMBL10666776 | 0.94 | HDAC1 (0.56) | HDAC7HDAC1SMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL10667117 | 0.94 | HDAC1 (0.56) | HDAC7HDAC1SMN1; SMN2TDP1L3MBTL1 | |
| SCHEMBL876560 | 0.90 | SMN1; SMN2 (0.53) | HDAC7HDAC1MMP2MMP9SMN1; SMN2 | |
| SCHEMBL7438587 | 0.86 | NPC1 (0.50) | HDAC7HDAC1HDAC8HDAC3HDAC4 | |
| SCHEMBL13691920 | 0.86 | HDAC1 (0.48) | HDAC7HDAC1MMP2MMP9SMN1; SMN2 | |
| SCHEMBL9219366 | 0.84 | MMP2 (0.55) | HDAC7HDAC1MMP2MMP9SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268810-B2 | Lipophilic chelates and their use in imaging | GUERBET (FR) | 2012-09-18 | — | — | US | disclosed |
| EP-2265615-A1 | IMIDAZOPYRIMIDINE, IMIDAZOPYRAZINE AND IMIDAZOPYRIDAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009115321-A1 | MIDAZOPYRIMIDINE, IMIDAZOPYRAZINE AND IMIDAZOPYRIDAZINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2009-09-24 | — | — | WO | disclosed |
| EP-2103614-A1 | Substituted imidazopyrimidine, imidazopyrazine and imidazopyridazine derivatives as melanocortin-4 receptor modulators | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2009-09-23 | — | — | EP | disclosed |
| US-20090214441-A1 | Lipophilic Chelates and Their Use in Imaging | GUERBET (FR) | 2009-08-27 | — | — | US | disclosed |
| EP-1480979-B1 | GADOLINIUM CHELATE OLIGOMERS, THEIR USE AS CONTRAST PRODUCTS IN MAGNETIC RESONANCE IMAGING AND THEIR SYNTHESIS INTERMEDIATES | GUERBET SA (FR) | 2007-05-02 | — | — | EP | disclosed |
| EP-1480979-A2 | GADOLINIUM CHELATE OLIGOMERS, THEIR USE AS CONTRAST PRODUCTS IN MAGNETIC RESONANCE IMAGING AND THEIR SYNTHESIS INTERMEDIATES | GUERBET (FR) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003074523-A2 | GADOLINIUM CHELATE OLIGOMERS, THEIR USE AS CONTRAST PRODUCTS IN MAGNETIC RESONANCE IMAGING AND THEIR SYNTHESIS INTERMEDIATES | GUERBET (FR) | 2003-09-12 | — | — | WO | disclosed |
| EP-0824544-B1 | PEPTIDYL COMPOUNDS WHICH INHIBIT METALLOPROTEINASE AND TNF LIBERATION AND THEIR THERAPEUTIC USE | DARWIN DISCOVERY LTD (GB) | 2003-04-16 | — | — | EP | disclosed |
| US-6180611-B1 | INHIBITORS OF MATRIX METALLOPROTEINASES AND TUMOR NECROSIS FACTOR | DARWIN DISCOVERY, LTD. (GB) | 2001-01-30 | — | — | US | disclosed |
| EP-0784629-B1 | PEPTIDYL COMPOUNDS AND THEIR THERAPEUTIC USE AS INHIBITORS OF METALLOPROTEASES | DARWIN DISCOVERY LTD (GB) | 1999-04-28 | — | — | EP | disclosed |
| US-5872146-A | Mercapto alkyl peptidyl compounds having MMP and TNF inhibitory activity | CHIROSCIENCE LIMITED (GB) | 1999-02-16 | — | — | US | disclosed |
| EP-0891328-A1 | PEPTIDYL COMPOUNDS HAVING MMP AND TNF INHIBITORY ACTIVITY | Darwin Discovery Limited (GB) | 1999-01-20 | — | — | EP | disclosed |
| CN-1193978-A | Peptidyl compounds and their therapeutic use as inhibitors of metalloproteases | CHIROSCIENCE LTD (GB) | 1998-09-23 | — | — | CN | disclosed |
| EP-0824544-A1 | PEPTIDYL COMPOUNDS WHICH INHIBIT METALLOPROTEINASE AND TNF LIBERATION AND THEIR THERAPEUTIC USE | Chiroscience Limited (GB) | 1998-02-25 | — | — | EP | disclosed |
| US-5712389-A | Polyaminated ligands and metal complexes thereof | GUERBET S.A. (FR) | 1998-01-27 | — | — | US | disclosed |
| WO-1997037973-A1 | PEPTIDYL COMPOUNDS HAVING MMP AND TNF INHIBITORY ACTIVITY | DARWIN DISCOVERY LIMITED (GB) | 1997-10-16 | — | — | WO | disclosed |
| EP-0784629-A1 | PEPTIDYL COMPOUNDS AND THEIR THERAPEUTIC USE AS INHIBITORS OF METALLOPROTEASES | Chiroscience Limited (GB) | 1997-07-23 | — | — | EP | disclosed |
| WO-1996035712-A1 | PEPTIDYL COMPOUNDS WHICH INHIBIT METALLOPROTEINASE AND TNF LIBERATION AND THEIR THERAPEUTIC USE | CHIROSCIENCE LIMITED (GB) | 1996-11-14 | — | — | WO | disclosed |
| WO-1996011209-A1 | PEPTIDYL COMPOUNDS AND THEIR THERAPEUTIC USE AS INHIBITORS OF METALLOPROTEASES | CHIROSCIENCE LIMITED (GB) | 1996-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090214441-A1 | Lipophilic Chelates and Their Use in Imaging | SLC40A1, TSPO, SLC47A2 | HDAC7 2481/4885HDAC1 1895/4885MMP2 3718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.